Want to see PFSA full AI Analyst Report?
Top Page
Profusa
(NASDAQ:PFSA)
Select Model
Select Model
Rating:40Underperform
Price Target:
$3.00
▼(-40.00% Downside)
Action:Downgraded
Date:08/29/26
The score is primarily held down by very weak financial performance (no revenue, widening losses, negative equity, and sustained cash burn), reinforced by bearish technicals (price far below key moving averages and negative MACD). Corporate events provide some potential balance-sheet improvement and strategic upside, but dilution and financing dependencies remain significant, and valuation signals are limited due to ongoing losses.
Positive Factors
Potential Diagnostics Revenue Platform
The diagnostics option could provide access to an established commercial revenue base and recurring provider relationships, materially broadening PFSA beyond pre-commercial biosensors. However, financing, debt, listing and shareholder conditions must be satisfied.
Negative Factors
No Commercial Revenue and Widening Losses
The absence of recorded revenue indicates PFSA remains pre-commercial, while widening losses show that operating expenses are increasing without a proven revenue engine. This limits visibility on operating leverage and makes successful commercialization critical to long-term viability.
Read all positive and negative factors
Positive Factors
Negative Factors
Potential Diagnostics Revenue Platform
The diagnostics option could provide access to an established commercial revenue base and recurring provider relationships, materially broadening PFSA beyond pre-commercial biosensors. However, financing, debt, listing and shareholder conditions must be satisfied.
Read all positive factors
Profusa (PFSA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.74M
Dividend YieldN/A
Average Volume (3M)2.24M
Price to Earnings (P/E)―
Beta (1Y)0.91
Revenue GrowthN/A
EPS Growth72.63%
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding605,647
10 Day Avg. Volume764,705
30 Day Avg. Volume2,239,120
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)-9.87
Price to Sales (P/S)0.00
P/FCF Ratio-16.19
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Profusa Business Overview & Revenue Model
Company Description
Profusa, Inc. is a pioneering health technology firm that engineers advanced, bio-integrated sensors. These innovative devices, exemplified by their Lumee™ Oxygen Platform, are designed for uninterrupted observation of internal physiological marke...
How the Company Makes Money
Profusa’s primary monetization model is expected to center on commercialization of its biosensing products and associated system components (e.g., implantable sensor units and external readers/wearables) and, where applicable, related services or ...
Profusa Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
9
Very Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -35.04M | -30.73M | -4.81M | -6.00M | -13.22M | -5.05M |
| Net Income | -42.97M | -35.82M | -9.23M | -10.28M | -20.22M | -10.31M |
Balance Sheet | ||||||
| Total Assets | 1.04M | 3.77M | 3.07M | 1.89M | 1.03M | 11.36M |
| Cash, Cash Equivalents and Short-Term Investments | 719.00K | 1.78M | 191.00K | 142.00K | 78.00K | 856.00K |
| Total Debt | 14.00M | 14.81M | 48.21M | 40.40M | 31.03M | 24.02M |
| Total Liabilities | 28.17M | 30.43M | 122.28M | 111.89M | 100.80M | 95.02M |
| Stockholders Equity | -27.13M | -26.66M | -119.20M | -110.00M | -99.77M | -83.66M |
Cash Flow | ||||||
| Free Cash Flow | -21.04M | -16.26M | -2.07M | -4.40M | -7.70M | -10.69M |
| Operating Cash Flow | -20.95M | -16.25M | -2.07M | -4.40M | -7.70M | -10.69M |
| Investing Cash Flow | -7.43M | -2.01M | 0.00 | -2.00K | 0.00 | 0.00 |
| Financing Cash Flow | 28.92M | 19.84M | 2.12M | 4.47M | 6.92M | 8.75M |
Profusa Risk Analysis
Profusa disclosed 80 risk factors in its most recent earnings report. Profusa reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Profusa Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $34.02B | 34.63 | 36.19% | ― | 15.54% | 77.43% | |
73 Outperform | $188.49B | 35.53 | 10.52% | 2.41% | 8.06% | -61.33% | |
68 Neutral | $117.81B | 22.54 | 14.22% | 3.43% | 9.77% | 12.28% | |
55 Neutral | $495.96M | -4.38 | -165.83% | ― | 90.63% | -11.42% | |
52 Neutral | $142.60M | -11.77 | -50.27% | ― | 27.98% | 87.35% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
40 Underperform | $1.74M | -0.01 | 148.25% | ― | ― | 72.63% |
* Healthcare Sector Average
PFSA
Profusa
2.62
-2,476.13
-99.89%
ABT
Abbott Laboratories
108.79
-21.02
-16.19%
DXCM
Dexcom
89.71
8.95
11.08%
MDT
Medtronic
93.10
3.17
3.53%
SENS
Senseonics Holdings
9.90
0.94
10.49%
OWLT
Owlet
5.03
-2.27
-31.10%
Profusa Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Profusa Strengthens Capital Structure Through Debt-to-Equity Exchange
Positive
Aug 21, 2026
On August 12, 2026, Profusa entered into a fifth amendment to its 2025 securities purchase agreement with Ascent Partners Fund, updating the amendment effective date, adding a new optional note form and resetting the exercise price of an existing ...
Shareholder MeetingsStock Split
Profusa Announces Approved Reverse Stock Split Implementation
Neutral
Aug 14, 2026
At its annual meeting on June 23, 2026, Profusa’s stockholders approved an amendment enabling a reverse stock split at a ratio within a specified range, with the final one-for-four split later set by the chief executive officer and filed wit...
Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsRegulatory Filings and Compliance
Profusa Secures Option for Major Diagnostics Acquisition
Positive
Jul 31, 2026
On July 31, 2026, Profusa entered into an Option Agreement granting it the right, but not the obligation, to acquire G3 Vision Labs and its diagnostics subsidiaries, which generated an estimated $111 million in 2025 net revenues, in a deal structu...
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and Financing
Profusa Plans Strategic Acquisition in Diagnostics Expansion
Positive
Jul 27, 2026
On July 27, 2026, Profusa announced it had signed a non-binding term sheet to acquire a privately held, commercial-stage health diagnostics and toxicology testing company, aiming to form a publicly traded diagnostics business with national CLIA-ce...
Financial DisclosuresRegulatory Filings and ComplianceShareholder MeetingsStock Split
Profusa Implements 1-for-25 Reverse Stock Split on Nasdaq
Neutral
Jul 6, 2026
At its annual meeting of stockholders on June 23, 2026, Profusa received shareholder approval to amend its certificate of incorporation to enable a reverse stock split at a ratio between 1-for-5 and 1-for-200, with the final terms delegated to the...
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and FinancingRegulatory Filings and ComplianceShareholder MeetingsStock Split
Profusa Shareholders Approve Reverse Split and Governance Changes
Neutral
Jun 23, 2026
At a virtual special meeting of stockholders held on June 23, 2026, Profusa shareholders elected Lauren Chung as a Class I director to serve until the 2029 annual meeting, with a quorum established from 1.82 million shares represented. Investors a...
Business Operations and StrategyPrivate Placements and Financing
Profusa Taps Equity Line With Dilutive True-Up Mechanism
Negative
Jun 8, 2026
On June 8, 2026, Profusa, Inc. submitted an Advance Notice to Ascent Partners Fund LLC to draw on their existing equity line of credit under a Securities Purchase Agreement dated July 28, 2025 and amended December 22, 2025. For Advance Notices fro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.